WallStreetZenWallStreetZen

NASDAQ: IKT
Inhibikase Therapeutics Inc Stock Ownership - Who owns Inhibikase Therapeutics?

OverviewForecastEarningsRevenueDividendOwnership

Insider buying vs selling

Have Inhibikase Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Sands Capital Life Sciences Pulse Fund II LP10% Owner2025-11-212,068,965$1.45
$3.00MBuy

1 of 1

IKT insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when IKT insiders and whales buy or sell their stock.

IKT Shareholders

What type of owners hold Inhibikase Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Sands Capital Life Sciences Pulse Fund II LP17.32%13,018,965$21.22MInsider
Sands Capital Alternatives LLC17.32%13,018,965$21.22MInstitution
Soleus Capital Management LP14.47%10,875,000$17.73MInstitution
Fairmount Funds Management LLC11.47%8,625,000$14.06MInstitution
Adar1 Capital Management LLC10.73%8,063,949$13.14MInstitution
Trails Edge Capital Partners LP8.22%6,178,124$10.07MInstitution
Blackstone Inc7.90%5,938,276$9.68MInstitution
Siren LLC7.78%5,850,000$9.54MInstitution
Perceptive Advisors LLC7.21%5,421,568$8.84MInstitution
Commodore Capital LP7.18%5,397,488$8.80MInstitution

1 of 3

IKT vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
IKT80.60%16.42%Net Buying
CLLS14.58%0.00%
ALEC64.04%35.96%Net SellingNet Selling
SLGL24.11%75.89%Net BuyingNet Buying
CAMP59.53%40.47%Net Buying
View Top Biotech Stocks

Inhibikase Therapeutics Stock Ownership FAQ

Who owns Inhibikase Therapeutics?

Inhibikase Therapeutics (NASDAQ: IKT) is owned by 80.60% institutional shareholders, 16.42% Inhibikase Therapeutics insiders, and 2.99% retail investors. Sands Capital Life Sciences Pulse Fund II LP is the largest individual Inhibikase Therapeutics shareholder, owning 13.02M shares representing 9.86% of the company. Sands Capital Life Sciences Pulse Fund II LP's Inhibikase Therapeutics shares are currently valued at $21.87M.

If you're new to stock investing, here's how to buy Inhibikase Therapeutics stock.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.